文献速递脊柱关节炎

ASAS健康指数测量性能:全球中轴型与外周型脊柱关节炎患者研究结果

Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis.
PubMed 文献 · Ann Rheum Dis · 2018-06-01

研究在23个国家1548例脊柱关节炎患者中评估ASAS健康指数(ASAS HI)英文原版及18个翻译版本的结构效度、可解释性、信度和反应性,并确定区分健康良好与不良的界值。结果显示ASAS HI效度、信度和反应性良好,≤5.0区分健康良好与中等健康,≥12.0区分健康不良与中等健康。

要点

  • ASAS HI结构效度从低(年龄相关系数0.10)到高(BASFI相关系数0.71)不等。
  • 578例稳定期患者重测信度良好,ICC=0.87(95%CI 0.84至0.89)。
  • 246例需升级治疗者反应性中等至较大,SRM因药物类别而异。

核心结论

  • ASAS HI被证明有效、可靠且具有反应性,可用于评估脊柱关节炎及其治疗对功能和健康的影响,并可进行人群间疾病影响比较。

研究设计与样本

  • 在23个国家纳入符合ASAS中轴型或外周型脊柱关节炎分类标准的代表性脊柱关节炎患者样本,评估ASAS HI英文原版及18个翻译版本的结构效度、可解释性、信度和反应性。

主要发现

  • 共纳入1548例患者,64.9%为男性,平均(SD)年龄42.0(13.4)岁。
  • 结构效度从低(年龄:0.10)到高(Bath强直性脊柱炎功能指数:0.71)不等,内部一致性高(Cronbach's α为0.93)。
  • 578例患者重测信度良好(ICC=0.87(95%CI 0.84至0.89))。
  • 246例患者反应性中等至较大(非甾体抗炎药SRM=-0.44,传统合成改善病情抗风湿药SRM=-0.69,肿瘤坏死因子抑制剂SRM=-0.85)。
  • 最小可检测变化为3.0;值≤5.0区分健康良好与中等健康具有平衡的特异性,值≥12.0对区分健康不良与中等健康具有特异性。

关键数值与推荐

  • ASAS HI值≤5.0区分健康良好与中等健康,≥12.0区分健康不良与中等健康。
  • 最小可检测变化为3.0。
  • 重测信度ICC=0.87(95%CI 0.84至0.89)。
  • 反应性SRM:非甾体抗炎药-0.44,传统合成改善病情抗风湿药-0.69,肿瘤坏死因子抑制剂-0.85。

临床怎么用

  • ASAS HI可用于评估脊柱关节炎及其治疗对功能和健康的影响。
  • ASAS HI可用于比较不同人群间的疾病影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate construct validity, interpretability, reliability and responsiveness as well as determination of cut-off points for good and poor health within the original English version and the 18 translations of the disease-specific Assessment of Spondyloarthritis international Society Health Index (ASAS HI) in 23 countries worldwide in patients with spondyloarthritis (SpA). METHODS: A representative sample of patients with SpA fulfilling the ASAS classification criteria for axial (axSpA) or peripheral SpA was used. The construct validity of the ASAS HI was tested using Spearman correlation with several standard health outcomes for axSpA. Test-retest reliability was assessed by intraclass correlation coefficients (ICCs) in patients with stable disease (interval 4-7 days). In patients who required an escalation of therapy because of high disease activity, responsiveness was tested after 2-24weeks using standardised response mean (SRM). RESULTS: Among the 1548 patients, 64.9% were men, with a mean (SD) age 42.0 (13.4) years. Construct validity ranged from low (age: 0.10) to high (Bath AnkylosingSpondylitisFunctioning Index: 0.71). Internal consistency was high (Cronbach's α of 0.93). The reliability among 578 patients was good (ICC=0.87 (95% CI 0.84 to 0.89)). Responsiveness among 246 patients was moderate-large (SRM=-0.44 for non-steroidal anti-inflammatory drugs, -0.69 for conventional synthetic disease-modifying antirheumatic drug and -0.85 for tumour necrosis factor inhibitor). The smallest detectable change was 3.0. Values ≤5.0 have balanced specificity to distinguish good health as opposed to moderate health, and values ≥12.0 are specific to represent poor health as opposed to moderate health. CONCLUSIONS: The ASAS HI proved to be valid, reliable and responsive. It can be used to evaluate the impact of SpA and its treatment on functioning and health. Furthermore, comparison of disease impact between populations is possible.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Kiltz U, van der Heijde D, Boonen A, et al. Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Ann Rheum Dis. 2018. PMID: 29858176. doi:10.1136/annrheumdis-2017-212076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。